New data were presented at the American Academy of Neurology annual meeting on the effect of oral cladribine on lymphocyte subsets in relapsing multiple sclerosis, providing new insights for evaluating the safety and efficacy of the drug. Oral cladribine is a cell-depleting disease-modifying drug, which was approved for use in Canada in November 2017. Read More
Report from the American Academy of Neurology annual meeting, Los Angeles, April 21-27, 2018
Thursday Edition
Wednesday Edition
Tuesday Edition Read More
The past decade has seen numerous criticisms of statistical methodology in biomedical research, fuelled in part by a ‘reproducibility crisis’ – the concern that many supposedly significant results cannot be replicated. The latest salvo was an editorial recently published in the Journal of the American Medical Association (Ioannidis JPA. JAMA 2018;319:1429-1430). Read More
An important advance in the treatment of migraine has been the development of agents that target calcitonin gene-related peptide (CGRP), a neuropeptide that has emerged as a key player in the neurobiology of migraine. Read More